BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.Financing

SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu

Related news

ELVNEnliven Therapeutics2026-06-11 20:05 EST

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

ZNTLZentalis2026-08-13 20:01 EST

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

CTMXCytomX Therapeutics, Inc.2026-08-06 20:15 EST

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

View all latest news

CytomX Therapeutics, Inc.

Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates. Varsetatug Masetecan Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY...

Recent company news

CTMXCytomX Therapeutics, Inc.2026-08-06 20:15 EST

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-08-03 12:00 EST

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CTMXCytomX Therapeutics, Inc.2026-07-30 12:00 EST

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

CTMXCytomX Therapeutics, Inc.2026-07-27 12:00 EST

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CTMXCytomX Therapeutics, Inc.2026-06-03 12:00 EST

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Stock data

Close
3.28 USD
Market cap
687.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States